Login to Your Account

Kezar in the ignition: Fuel immunoproteasome effort with $50M

By Randy Osborne
Staff Writer

Tuesday, July 25, 2017

The scientific campaign for a better version of Velcade for multiple myeloma that began at Proteolix Inc. survived two mergers and ultimately failed, but led to the formation of Kezar Life Sciences Inc., with a promising approach, not to cancer but to autoimmune disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription